Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)

Leukemia

Volumn 25, Issue 5, 2011, Pages 856-867

  Drakos, E ^a   Singh, R R ^a   Rassidakis, G Z ^a,b   Schlette, E ^a   Li, J ^a   Claret, F X ^a   Ford Jr , R J ^a   Vega, F ^a   Medeiros, L J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

BCL2; diffuse large B cell lymphoma; MDM2; Nutlin; p53; t(14; 18)(q32; q21)

Indexed keywords

CASPASE 3; CASPASE 9; DOXORUBICIN; NUTLIN 3; PIFITHRIN ALPHA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; PROTEIN P73; PUMA PROTEIN; SERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DEPHOSPHORYLATION; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TRANSLOCATION LINE; TUMOR XENOGRAFT; UPREGULATION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMIDAZOLES; IMMUNOPRECIPITATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, SCID; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955799680     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.28     Document Type: Article

References (51)

1. Harris NL, Nathwani BN, Swerdlow SH, de Jong D, Jaffe ES, Yoshino T et al. Follicular Lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, (4th edn) IARC Press, 2008, 220-226.
2. Stein H, Chan JKC, Warnke RA, Gatter KC, Chan WC, Campo E et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, (4th edn) IARC Press: Lyon, France, 2008, 233-237.
3. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23: 6358-6363. (Pubitemid 46218847)
4. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88. (Pubitemid 19098870)
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53. (Pubitemid 21917115)
6. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-665. (Pubitemid 46232887)
7. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660. (Pubitemid 46232886)
8. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848. (Pubitemid 38174664)
9. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-1893. (Pubitemid 43228788)
10. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993-1000. (Pubitemid 44154636)
11. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150-3159. (Pubitemid 41565913)
12. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M et al. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 2007; 13: 3380-3387. (Pubitemid 46944926)
13. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106: 3609-3617. (Pubitemid 41609200)
14. Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 2007; 117: 1019-1028. (Pubitemid 46556758)
15. Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008; 22: 730-739. (Pubitemid 351552622)
16. Janz M, Stuhmer T, Vassilev LT, Bargou RC. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia 2007; 21: 772-779. (Pubitemid 46444562)
17. Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 4122-4129. (Pubitemid 43726822)
18. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109-4114. (Pubitemid 43726820)
19. Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res 2009; 15: 933-942.
20. Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ et al. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 2009; 23: 784-790.
21. Drakos E, Atsaves V, Schlette E, Li J, Papanastasi I, Rassidakis GZ et al. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia 2009; 23: 2290-2299.
22. Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo F, Albertson DG et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 2003; 101: 3109-3117. (Pubitemid 36858004)
23. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289-2295. (Pubitemid 23304250)
24. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994-2004. (Pubitemid 23293979)
25. Moller MB, Ino Y, Gerdes AM, Skjodt K, Louis DN, Pedersen NT. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 1999; 13: 453-459. (Pubitemid 29108084)
26. Davies AJ, Lee AM, Taylor C, Clear AJ, Goff LK, Iqbal S et al. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 2005; 19: 1459-1465. (Pubitemid 41136342)
27. Ford RJ, Goodacre A, Ramirez I, Mehta SR, Cabanillas F. Establishment and characterization of human B-cell lymphoma cell lines using B-cell growth factor. Blood 1990; 75: 1311-1318. (Pubitemid 20107299)
28. Leventaki V, Drakos E, Medeiros LJ, Lim MS, Elenitoba-Johnson KS, Claret FX et al. NPM-ALK oncogenic kinase promotes cell cycle progression through activation of JNK/cJun signaling in anaplastic large cell lymphoma. Blood 2007; 110: 1621-1630. (Pubitemid 47443980)
29. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem 1994; 269: 26865-26870. (Pubitemid 24332884)
30. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001; 15: 515-522. (Pubitemid 32266720)
31. Deng X, Gao F, Flagg T, Anderson J, May WS. Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol 2006; 26: 4421-4434. (Pubitemid 43877564)
32. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737. (Pubitemid 29428873)
33. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2: 474-479. (Pubitemid 44266309)
34. Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Lowdell MW et al. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood 2009; 114: 1217-1225.
35. Galluzzi L, Morselli E, Kepp O, Tajeddine N, Kroemer G. Targeting p53 to mitochondria for cancer therapy. Cell cycle 2008; 7: 1949-1955. (Pubitemid 352030339)
36. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49: 223-241.
37. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 2008; 27: 5303-5314.
38. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008; 27: 997-1003. (Pubitemid 351225385)
39. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007; 26: 3473-3481. (Pubitemid 46816754)
40. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127: 1323-1334. (Pubitemid 44960417)
41. Knoops L, Haas R, de Kemp S, Majoor D, Broeks A, Eldering E et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 2007; 110: 1116-1122. (Pubitemid 47281406)
42. Renouf B, Hollville E, Pujals A, Tetaud C, Garibal J, Wiels J. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. Leukemia 2009; 23: 1557-1563.
43. Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D et al. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage-independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 2008; 14: 5416-5425.
44. Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H et al. Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation. J Biol Chem 2000; 275: 21661-21667. (Pubitemid 30481874)
45. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 2006; 5: 2778-2786. (Pubitemid 44901740)
46. Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Nacheva EP et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood 2008; 112: 3827-3834.
47. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005; 309: 1732-1735. (Pubitemid 41285944)
48. Pellecchia M, Reed JC. Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy. Curr Pharm Des 2004; 10: 1387-1398. (Pubitemid 38559755)
49. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1181-1189. (Pubitemid 351555542)
50. Wade M, Rodewald LW, Espinosa JM, Wahl GM. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle 2008; 7: 1973-1982. (Pubitemid 352030342)
51. Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer 2009; 8: 115.